Blog

DEEP RESEARCH · OliX (KOSDAQ 226950)

OliX: From platform validation to clinical harvest

cp-asiRNA platform, the Eli Lilly MASH deal, and the three 2026 catalysts

Date: 2026-01-16 · RNAi pipeline, competition and financial analysis · Naver blog source

Investment decisions are your own responsibility. This is research, not a recommendation.

0. Bottom line first

Backed by its asymmetric siRNA (asiRNA) and cell-penetrating asiRNA (cp-asiRNA) platforms, OliX shifts from “platform validation” to “commercial-value realization” in 2026, anchored by the Eli Lilly MASH/cardiometabolic deal. The three 2026 catalysts: ① OLX75016 (MASH) Phase 2 entry, ② OLX301A (AMD) global L/O or Phase 2 start, ③ OLX104C (hair loss) Phase 2a efficacy readout.

1. RNAi’s ‘third wave’ and OliX’s position

Global RNAi technology market is projected to grow from USD 2.75B in 2024 to USD 6.63B by 2033 (CAGR 10.4%). APAC is the fastest-growing region (CAGR 16.01%, 2026–2031). PR Newswire, Mordor Intelligence.

Interpretation: The two RNAi barriers are delivery and off-target effects. Alnylam solved liver delivery via GalNAc but extrahepatic delivery is still hard. OliX uses cp-asiRNA to deliver without LNPs to skin/eye/lung — a distinct niche.

2. Market: a USD 25B MASH opportunity

The global MASH (formerly NASH) market is projected to grow to ~USD 25.3B by 2026. Madrigal’s Rezdiffra is FDA-approved but oral dosing and hepatotoxicity monitoring are limitations; Lilly’s Zepbound shows strong weight loss but with muscle-loss concerns. LiverTox — Resmetirom, FDA approval analysis.

3. Platform: asiRNA → cp-asiRNA

OliX platformOff-target suppression + self-delivery
asiRNAAsymmetric design only loads antisense strand
cp-asiRNALipophilic conjugate enables self-delivery
Lower toxicityNo LNP needed
Indication scopeSkin, eye, lung + liver (GalNAc)
Tackles delivery and off-target simultaneously.

asiRNA uses an asymmetric strand design so only the antisense strand loads into RISC — sharply lowering off-target effects vs Alnylam/Arrowhead. cp-asiRNA attaches a lipophilic group so the molecule penetrates cell membranes without LNPs. FirstWord — TIDES 2020, PharmaVoice, Therapeutic siRNA — PMC.

4. Key pipelines — 2026 momentum

4.1 OLX75016 (MASH / obesity) — Lilly partnership

Competitor comparison

FeatureOLX75016 (OliX)Rezdiffra (Madrigal)Zepbound (Eli Lilly)
MechanismMARC1 silencing (RNAi)THR-β agonistGLP-1 / GIP dual agonist
Route / frequencySC, every 3–6 months (long-acting)Oral, once dailySC, once weekly
Key dataPreclinical: synergy with GLP-1, fatty-liver improvementPhase 3: fibrosis improvement, MASH resolution (FDA approved)Phase 2: MASH resolution up to 73.3%, fibrosis improvement
SafetyLiver-specific delivery → minimal systemic toxicity expectedDiarrhea, nausea, liver-toxicity monitoringGI side effects, muscle-loss concerns
DifferentiatorConvenient dosing + muscle-sparing fat lossFirst oral MASH drugStrong weight loss, ideal for obese MASH

4.2 OLX301A (wet/dry AMD)

Silences both neovascular and inflammatory genes in the eye. Unlike Eylea/Lucentis that only target VEGF, OLX301A also controls the inflammatory pathway — a potential option for anti-VEGF refractory patients. The 2024 rights return from Théa was due to Théa’s internal strategy, not efficacy. The completed 2025 US Phase 1 showed safety and BCVA improvement potential. KBR — Phase 1 safety, FirstWord — Théa collaboration, KBR — Théa rights return, Glance by Eyes On Eyecare, FirstWord — OTS 2020.

OliX pipeline progress and Eli Lilly partnership

4.3 OLX104C (androgenetic alopecia)

Silences androgen receptor (AR) only in scalp tissue; degrades quickly if it reaches blood, eliminating finasteride-style systemic side effects (sexual dysfunction, depression). Phase 1 done in Australia; first patient dosed in Phase 1b/2a in late 2025. 2026 expects Phase 2a efficacy data — potentially the first RNAi hair-loss therapeutic to show efficacy in humans. FirstWord — preclinical, KBR — World Congress for Hair Research, Biospectator — AR RNAi 1b/2a first dose, KBR — L’Oréal RNAi partnership.

5. Financials & risk

5.1 Cashflow / capital

  • Aug-2025 KRW 115B convertible preferred stock issuance. KBR, Webull debt analysis
  • Lilly upfront + end-2025 estimated cash ~KRW 131.5B → R&D covered.
  • From 2026, milestone revenues turn OliX into a revenue-generating biotech.

5.2 CB overhang resolved

Of KRW 14.7B CB, ~KRW 4.6B was called and re-sold to US hedge fund Weiss Asset Management for ~KRW 10.1B, sharply reducing near-term selling overhang. KBR, Bondweb.

5.3 Clinical risk

Interpretation: 2026 is the Phase 2 entry zone — a ‘valley of death’ window. FDA endpoints for MASH are strict; monitor Lilly’s trial design and execution closely.

6. 2026 milestones & rationale

M1 · MASH

OLX75016 Phase 2 entry

Australia Phase 1 MAD wraps H1-26 → Lilly’s competitive pressure vs Novo means immediate Phase 2 → milestone payments.

M2 · AMD

OLX301A global L/O or Phase 2

With clinical data in hand, negotiate at higher valuation. JPM 2026 catalyst accelerates the timeline.

M3 · Alopecia

OLX104C Phase 2a efficacy

Positive hair-count data could trigger L/O with L’Oréal or other beauty/consumer-health players.

7. Summary

  1. Investment thesis: The Lilly deal validates OliX globally. 2026 turns the partnership into Phase 2 progress and real cashflow.
  2. Risk management: Portfolio diversified across metabolic, ophthalmic and dermatologic. CB overhang preemptively addressed.
  3. Conclusion: 2026 is the peak of a ‘Big Cycle’ — H2-26 MASH Phase 2 entry plus hair-loss efficacy data are the key catalysts.

Appendix: competitor comparison

IndicationOliX programMajor competitorOliX differentiation
MASHOLX75016 (Lilly)Rezdiffra (Madrigal)Long-acting injection, muscle-sparing fat loss
AMDOLX301AEylea (Regeneron/Bayer)Anti-VEGF refractory + dry AMD extension
Hair lossOLX104CFinasteride (Merck)Scalp-local action, no systemic side effects

Sources

Naver original